F. Hoffmann-La Roche Ltd (ROG):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C13542)
◆英語タイトル:F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C13542
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年2月
◆ページ数:88
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

F. Hoffmann-La Roche Ltd (ROG) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics to treat major diseases. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory disease areas. The company also provides in vitro diagnostics and tissue-based cancer diagnostics, besides diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose and treat diseases. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries all over the world. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd Key Recent Developments

Feb 06,2019: Chugai Pharmaceutical has announced that Roche has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, an initiative leading the effort to change the lack of acce…Read more
Feb 05,2019: Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Feb 04,2019: BRIEF-Senseonics Announces Extension Of Distribution Agreement With Roche Diabetes Care
Jan 31,2019: Roche reports very strong results in 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
F. Hoffmann-La Roche Ltd – Key Facts
F. Hoffmann-La Roche Ltd – Key Employees
F. Hoffmann-La Roche Ltd – Key Employee Biographies
F. Hoffmann-La Roche Ltd – Major Products and Services
F. Hoffmann-La Roche Ltd – History
F. Hoffmann-La Roche Ltd – Company Statement
F. Hoffmann-La Roche Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
F. Hoffmann-La Roche Ltd – Business Description
Business Segment: Diagnostics
Overview
Performance
Key Stats
Business Segment: Pharmaceuticals
Overview
Performance
Key Stats
Geographical Segment: Africa, Australia and Oceania
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: North America
Performance
R&D Overview
F. Hoffmann-La Roche Ltd – Corporate Strategy
F. Hoffmann-La Roche Ltd – SWOT Analysis
SWOT Analysis – Overview
F. Hoffmann-La Roche Ltd – Strengths
F. Hoffmann-La Roche Ltd – Weaknesses
F. Hoffmann-La Roche Ltd – Opportunities
F. Hoffmann-La Roche Ltd – Threats
F. Hoffmann-La Roche Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
F. Hoffmann-La Roche Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 06, 2019: Chugai Pharmaceutical has announced that Roche has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, an initiative leading the effort to change the lack of acce…Read more
Feb 05, 2019: Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Jan 31, 2019: Roche reports very strong results in 2018
Jan 24, 2019: Genentech announces Alexander Hardy as Chief Executive Officer
Jan 17, 2019: FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Jan 15, 2019: Roche launches uPath enterprise software with improved speed, performance and usability for digital pathology
Dec 17, 2018: PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)
Dec 12, 2018: Roche, Merck partner to develop pan-cancer companion diagnostic test
Dec 10, 2018: New member proposed for election to Roche Board of Directors
Dec 05, 2018: FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
F. Hoffmann-La Roche Ltd, Key Facts
F. Hoffmann-La Roche Ltd, Key Employees
F. Hoffmann-La Roche Ltd, Key Employee Biographies
F. Hoffmann-La Roche Ltd, Major Products and Services
F. Hoffmann-La Roche Ltd, History
F. Hoffmann-La Roche Ltd, Subsidiaries
F. Hoffmann-La Roche Ltd, Key Competitors
F. Hoffmann-La Roche Ltd, Ratios based on current share price
F. Hoffmann-La Roche Ltd, Annual Ratios
F. Hoffmann-La Roche Ltd, Annual Ratios (Cont...1)
F. Hoffmann-La Roche Ltd, Annual Ratios (Cont...2)
F. Hoffmann-La Roche Ltd, Interim Ratios
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
F. Hoffmann-La Roche Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
F. Hoffmann-La Roche Ltd, Performance Chart (2014 - 2018)
F. Hoffmann-La Roche Ltd, Ratio Charts
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ F. Hoffmann-La Roche Ltd (ROG):企業の財務・戦略的SWOT分析(F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆